Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
clinical trials
fda
7
×
life sciences
national blog main
boston blog main
boston top stories
national top stories
new york blog main
new york top stories
san diego blog main
san francisco blog main
san francisco top stories
boston
europe top stories
indiana blog main
san diego top stories
boston university
deals
eli lilly
europe blog main
indiana top stories
investing
national
novartis
raleigh-durham blog main
roche
seattle blog main
type 1 diabetes
venture capital
akcea therapeutics
alnylam pharmaceuticals
arena pharmaceuticals
arrowmark partners
barry greene
beta bionics
bial
bigfoot biomedical
billy dunn
biofourmis
What
patients
7
×
fda
drug
medicine
daily
diabetes
friday
million
startup
time
add
ago
alnylam
analytics
approval
approve
approved
atrophy
awaits
beta
bid
biofourmis
biological
bionics
blood
boehringer
called
cancer
carbidopa
closed
combination
control
crossed
data
decades
decision
developing
device
devices
digital
Language
unset
Current search:
fda
×
biotech
×
patients
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision